Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 15, 2007

View Archived Issues

Targeting the hepatic phase of malaria infection proves effective in animal studies

Interim data from ragweed study of Tolamba

Antibacterial activity of Indonesian traditional remedy confirmed by Mayo Clinic researchers

New phase I trial investigates suicide gene therapy in pancreatic adenocarcinoma

Recent AstraZeneca patents describe novel therapeutic agents for thrombotic disorders

Recent AstraZeneca patent describes new treatment option for arrhythmia

Recent patents report novel contraceptives and therapeutic agents for sexual dysfunction

Orthovisc studied in osteoarthritis of the shoulder joint

Phase I/II study evaluates Neuprex in HSCT

MP-12 Rift Valley fever vaccine to be evaluated in phase II study

Seattle Genetics and Agensys to develop ADC therapies for cancer

Organon and AMC collaborate on novel therapy for rheumatoid arthritis

Epiphany completes license for KSHV

Fispemifene significantly increases testosterone in androgen-deficient men

Phase I study of VAS-203 cleared to begin in Germany

DelSite grants GelSite license to EndoBiologics for bacillary dysentery vaccine

Speedel studies new renin inhibitor SPP-1148 in phase I

Studies of Cleveland's Protectans 600 series reveal new stem cell discovery

Endoscopic ultrasound administration of TNFerade cleared for use in PACT trial

Voraxaze progress updated

International launch of Promus everolimus-eluting stent

Humanetics to begin phase I trials for BIO-300 for ARS

Forest completes acquisition of Cerexa

PBI-1402 studied in anemic patients with chronic kidney disease

Rotigotine transdermal patch reduces RLS symptoms in second phase III study

Swedish MPA approves Cipralex in OCD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...